30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)
- Poster presentation
- Open Access
Antibody targeted CpG for the immunotherapy of solid tumors
Journal for ImmunoTherapy of Cancer volume 3, Article number: P287 (2015)
This work describes a method to improve the therapeutic effects of unmethylated CpG oligodeoxynucleotides (ODNs) analogues which can be used to stimulate the innate immune system. It is based upon the generation of novel reagents that can be used to target tumors after linkage of CpG ODNs analogues to tumor targeting monoclonal antibodies. This approach to cancer immunotherapy is novel in concept and will yield important information regarding the effectiveness of components of innate immunity in the treatment of cancer and related diseases and its ability to alter the tumor microenvironment. CpG has been used exclusively as adjuvants by injection locally at the site of interest or mixed with a tumor vaccine. For systemic diseases such as cancer, however, the local administration of CpG would limit the potential of this TLR agonist in the clinic.
In order to generate a reagent that can be used systemically, we have linked chemically active CpG motifs analogues to tumor targeting antibodies (chTNT-3) such as those that target tumor necrosis. In vitro and in vivo studies were also performed to demonstrate that conjugation of CpG to chTNT-3 retained the immunostimulatory activity of the CpG moiety and the binding ability of the chTNT-3 antibody.
These studies validate the usefulness of this novel approach and showed that, compared with the free CpG, the chTNT-3/CpG immunoconjugate is able to stimulate the immune system in vitro and reduce tumor burden as a monotherapeutic agent in vivo. Intraperitoneal injections of chTNT-3/CpG delayed tumor growth and improved survival in both high and low immunogenic tumor models, and was not significantly different than intratumoral injections of free CpG. Compared to saline-treated mice, chTNT-3/CpG-treated mice had decreased tumor volumes by as much as 70-79 % in two diversely different tumor mouse models. Systemically delivered free CpG and CpG conjugated to an isotype control antibody did not reduce tumor burden or improve survival.
These studies demonstrate the feasibility of antibody-CpG immunoconjugates for targeted therapy of innate immunity in different types of tumors and provide the foundation for near future development and clinical cancer immunotherapy evaluation.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Epstein, A.L., Jang, J., Hu, P. et al. Antibody targeted CpG for the immunotherapy of solid tumors. j. immunotherapy cancer 3 (Suppl 2), P287 (2015). https://doi.org/10.1186/2051-1426-3-S2-P287
- Cancer Immunotherapy
- Delay Tumor Growth
- Isotype Control Antibody
- Tumor Mouse Model
- Immunostimulatory Activity